MADRIGAL PHARMACEUTICALS INC (MDGL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MDGL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MDGL | Class I Director | 64 | ["Over 30 years of experience in the biopharmaceutical industry","Executive Vice President and Chief Commercial Officer at Incyte from 2012 until 2015","Various leadership positions at Amgen, Inc. from 2002 to 2011","Over 16 years with Glaxo Wellcome/GlaxoSmithKline","Served on the board of directors of Bellicum Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.","B.S. in Pharmacy and an M.B.A. from the University at Buffalo"] | ["Science and Technology","Nominating and Governance"] | 2026 |
Companies shown below are based on exact name match for the selected Director
Biography sourced from the proxy statement filing.
Possesses over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry. Served as Executive Vice President and Chief Commercial Officer at Incyte from 2012 until his retirement in 2015. Held various leadership positions from 2002 to 2011 at Amgen, Inc., including as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Spent over 16 years with Glaxo Wellcome/GlaxoSmithKline from 1985 to 2001, where he held roles of increasing responsibility, including as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit. Previously served on the board of directors of Bellicum Pharmaceuticals, Inc. from May 2016 to May 2022 and Halozyme Therapeutics, Inc. from February 2016 to December 2023. Mr. Daly earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York. Other Company Board Service Mr. Daly serves on the board of directors of the following publicly traded companies: Acadia since January 2016 argenx SE since May 2018 Cytokinetics Inc. since August 2025 Qualifications We believe that Mr. Daly is qualified to serve on our Board due to his extensive experience as a pharmaceutical executive leading major commercialization programs and his extensive experience as a director of public biopharmaceutical companies.